Myeloid Cell Leukemia-1 (MCL-1) siRNA Therapy Showed Cytotoxic Effect on T Cells Acute Lymphoblastic Leukemia

T-lineage acute lymphoblastic leukemia (T-ALL) is a malignant hyperplastic disease of the hematopoietic system. This tumor is the most common tumor in children and adolescents. Myeloid cell leukemia-1 (Mcl-1) is described as a prosurvival protein from the Bcl2 family. It is an important factor in routine cancer treatments. In fact, in different types of cancers, Mcl-1 downregulation can be a potential target. The present study aims to evaluate the cytotoxic effect of MCL-1 siRNA in T-ALL cells. The present study evaluated the effects of Mcl-1 small interfering RNAs (siRNAs) on survival in Jurkat cells. Specific Mcl-1 siRNA was transfected and using quantitative real-time PCR, the relative expression of Mcl-1 mRNA was determined. Moreover, cell survival was determined using the colorimetric MTT assay. The expression of mRNA reduced effectively in a dose-dependent manner at 48 hours after transfection with Mcl-1 siRNA. In addition, Mcl-1 siRNA treatment could significantly reduce tumor cell survival. Based on the results, downregulation of Mcl-1 by specific siRNAs in T-ALL cells can effectively reduce cell survival. Therefore, Mcl-1 siRNA may be a complementary agent along with standard methods in the treatment of T-ALL.